You are here

COVID-19

As the Coronavirus Spreads, Drug Pricing Legislation Remains Stalled

As the Coronavirus Spreads, Drug Pricing Legislation Remains Stalled

NY Times, NY

Flag link:

Gilead's long-awaited remdesivir price is $3,120, in line with watchdog estimates

Gilead's long-awaited remdesivir price is $3,120, in line with watchdog estimates

Fierce Pharma

Gilead Sciences

Flag link:

After CureVac nabs government backing, BioNTech sees $250M private investment

After CureVac nabs government backing, BioNTech sees $250M private investment

Fierce Biotech

Flag link:

Moderna and Catalent announce collaboration for fill-finish manufacturing of Moderna’s Covid-19 vaccine candidate

Moderna and Catalent announce collaboration for fill-finish manufacturing of Moderna’s Covid-19 vaccine candidate

Pharmaceutical Business Review

Moderna Therapeutics

drug manufacturing

Flag link:

Ending The Coronavirus Pandemic — What Will It Take?

Ending The Coronavirus Pandemic — What Will It Take?

Forbes

Flag link:

Sanofi Streamlines Pipeline Focus While Looking Ahead to a Post-COVID-19 World

Sanofi Streamlines Pipeline Focus While Looking Ahead to a Post-COVID-19 World

BioSpace

Flag link:

WHO, global partners launch $18B COVID-19 vaccine initiative

WHO, global partners launch $18B COVID-19 vaccine initiative

Fierce Pharma

Flag link:

FDA's on the air: Agency puts coronavirus front and center in podcast debut

FDA's on the air: Agency puts coronavirus front and center in podcast debut

Fierce Pharma

Flag link:

AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful

AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful

Fierce Pharma

University of Oxford

Flag link:

COVID-19 drug remdesivir recommended for EU approval

COVID-19 drug remdesivir recommended for EU approval

Pharmaforum

Flag link:

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903

Pharmaceutical Business Review

clinical trials

acute lung injury

Flag link:

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

Fierce Pharma

immuno-oncology

checkpoint inhibitors

Bristol-Meyers Squibb

Flag link:

When Covid-19 hits the brain, it can cause strokes, psychosis and a dementia-like syndrome, new survey shows

When Covid-19 hits the brain, it can cause strokes, psychosis and a dementia-like syndrome, new survey shows

Stat

neurological disorders

Flag link:

Vaccine alliance finds manufacturing capacity for 4 billion doses of coronavirus vaccines

Vaccine alliance finds manufacturing capacity for 4 billion doses of coronavirus vaccines

Reuters

drug manufacturing

Flag link:

Moderna aims for light-speed COVID-19 shot rollout with Catalent fill-finish deal

Moderna aims for light-speed COVID-19 shot rollout with Catalent fill-finish deal

Fierce Pharma

Moderna Therapeutics

Flag link:

Fauci: Trump never asked to slow down testing, 'cautiously optimistic' about vaccine by 2021

Fauci: Trump never asked to slow down testing, 'cautiously optimistic' about vaccine by 2021

BioPharma Dive

Flag link:

BMS launches digital Advocacy Exchange for patient groups affected by COVID-19

BMS launches digital Advocacy Exchange for patient groups affected by COVID-19

Pharmaforum

Bristol-Myers Squibb

Flag link:

AstraZeneca COVID-19 Vaccine Shows Promise in 2-Dose Animal Trial

AstraZeneca COVID-19 Vaccine Shows Promise in 2-Dose Animal Trial

Motley Fool

Pirbright Institute

animal research

Flag link:

Hahn testifies on COVID-19 response, says FDA on target to hit user fee goals

Hahn testifies on COVID-19 response, says FDA on target to hit user fee goals

RAPS.org

Flag link:

3 ways health tech is rising to the COVID challenge

3 ways health tech is rising to the COVID challenge

Pharmaforum

artificial intelligence

Flag link:

Pages